A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. Despite the advances in surgery, radiotherapy and chemotherapy, patient survival averages only 14.6 months. In most GBM tumors, tyrosine kinases show increased activity and/or expression and actively contribute to t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Nehoff, Hayley, Parayath, Neha N., McConnell, Melanie J., Taurin, Sebastien, Greish, Khaled
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2015
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741976/
https://ncbi.nlm.nih.gov/pubmed/26517812
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires